Lake Street raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $14 from $11 and keeps a Buy rating on the shares after the company announced interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia that the firm sees “materially” improving the prospects for DM199 in this indication.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Therapeutics price target raised to $12 from $10 at H.C. Wainwright
- DiaMedica Announces Positive Interim Results for DM199 Study
- DiaMedica Therapeutics reports interim results from DM199 study
- ReMEDy2 Trial: A New Hope for Acute Ischemic Stroke Treatment
- DiaMedica Therapeutics to be included in Russell 2000, 3000 Indexes